Seborrheic Dermatitis and Dandruff: A Comprehensive Review

Luis J Borda, Tongyu C Wikramanayake, Luis J Borda, Tongyu C Wikramanayake

Abstract

Seborrheic Dermatitis (SD) and dandruff are of a continuous spectrum of the same disease that affects the seborrheic areas of the body. Dandruff is restricted to the scalp, and involves itchy, flaking skin without visible inflammation. SD can affect the scalp as well as other seborrheic areas, and involves itchy and flaking or scaling skin, inflammation and pruritus. Various intrinsic and environmental factors, such as sebaceous secretions, skin surface fungal colonization, individual susceptibility, and interactions between these factors, all contribute to the pathogenesis of SD and dandruff. In this review, we summarize the current knowledge on SD and dandruff, including epidemiology, burden of disease, clinical presentations and diagnosis, treatment, genetic studies in humans and animal models, and predisposing factors. Genetic and biochemical studies and investigations in animal models provide further insight on the pathophysiology and strategies for better treatment.

Keywords: Dandruff; Epidermal barrier; Malassezia; Sebaceous gland; Seborrheic dermatitis.

Figures

Figure 1
Figure 1
Predisposing factors and their interactions in the pathogenesis of seborrheic dermatitis and dandruff.

References

    1. Gupta AK, Madzia SE, Batra R. Etiology and management of Seborrheic dermatitis. Dermatology. 2004;208:89–93.
    1. Del Rosso JQ. Adult seborrheic dermatitis: a status report on practical topical management. J Clin Aesthet Dermatol. 2011;4:32–38.
    1. Sampaio AL, Mameri AC, Vargas TJ, Ramos-e-Silva M, Nunes AP, et al. Seborrheic dermatitis. An Bras Dermatol. 2011;86:1061–1071.
    1. Schwartz RA, Janusz CA, Janniger CK. Seborrheic dermatitis: an overview. Am Fam Physician. 2006;74:125–130.
    1. Dessinioti C, Katsambas A. Seborrheic dermatitis: etiology, risk factors, and treatments: facts and controversies. Clin Dermatol. 2013;31:343–351.
    1. Foley P, Zuo Y, Plunkett A, Merlin K, Marks R. The frequency of common skin conditions in preschool-aged children in Australia: seborrheic dermatitis and pityriasis capitis (cradle cap) Arch Dermatol. 2003;139:318–322.
    1. Clark GW, Pope SM, Jaboori KA. Diagnosis and treatment of seborrheic dermatitis. Am Fam Physician. 2015;91:185–190.
    1. Naldi L, Rebora A. Clinical practice. Seborrheic dermatitis. N Engl J Med. 2009;360:387–396.
    1. Gupta AK, Bluhm R, Cooper EA, Summerbell RC, Batra R. Seborrheic dermatitis. Dermatol Clin. 2003;21:401–412.
    1. Dunic I, Vesic S, Jevtovic DJ. Oral candidiasis and seborrheic dermatitis in HIV-infected patients on highly active antiretroviral therapy. HIV Med. 2004;5:50–54.
    1. Lally A, Casabonne D, Newton R, Wojnarowska F. Seborrheic dermatitis among Oxford renal transplant recipients. J Eur Acad Dermatol Venereol. 2010;24:561–564.
    1. Ozcan D, Seckin D, Ada S, Haberal M. Mucocutaneous disorders in renal transplant recipients receiving sirolimus-based immunosuppressive therapy: a prospective, case-control study. Clin Transplant. 2013;27:742–748.
    1. Okada K, Endo Y, Fujisawa A, Tanioka M, Kabashima K, et al. Refractory seborrheic dermatitis of the head in a patient with malignant lymphoma. Case Rep Dermatol. 2014;6:279–282.
    1. Nnoruka EN, Chukwuka JC, Anisuiba B. Correlation of mucocutaneous manifestations of HIV/AIDS infection with CD4 counts and disease progression. Int J Dermatol. 2007;46(Suppl 2):14–18.
    1. Ramos-E-Silva M, Sampaio AL, Carneiro S. Red face revisited: Endogenous dermatitis in the form of atopic dermatitis and seborrheic dermatitis. Clin Dermatol. 2014;32:109–115.
    1. Maietta G, Fornaro P, Rongioletti F, Rebora A. Patients with mood depression have a high prevalence of seborrhoeic dermatitis. Acta Derm Venereol. 1990;70:432–434.
    1. Mastrolonardo M, Diaferio A, Logroscino G. Seborrheic dermatitis, increased sebum excretion, and Parkinson’s disease: a survey of (im) possible links. Med Hypotheses. 2003;60:907–911.
    1. Barba A, Piubello W, Vantini I, Caliari S, Cocchetto R, et al. Skin lesions in chronic alcoholic pancreatitis. Dermatologica. 1982;164:322–326.
    1. Cribier B, Samain F, Vetter D, Heid E, Grosshans E. Systematic cutaneous examination in hepatitis C virus infected patients. Acta Derm Venereol. 1998;78:355–357.
    1. Bilgili SG, Akdeniz N, Karadag AS, Akbayram S, Calka O, et al. Mucocutaneous disorders in children with down syndrome: case-controlled study. Genet Couns. 2011;22:385–392.
    1. Tegner E. Seborrhoeic dermatitis of the face induced by PUVA treatment. Acta Derm Venereol. 1983;63:335–339.
    1. Manuel F, Ranganathan S. A new postulate on two stages of dandruff: a clinical perspective. Int J Trichology. 2011;3:3–6.
    1. Schwartz JR, Cardin CW, Dawson TL. Seborrheic dermatitis and dandruff. In: Baran R, Maibach HI, editors. Textbook of Cosmetic dermatology. London: Martin Dunitz, Ltd; 2010. pp. 230–241.
    1. Bickers DR, Lim HW, Margolis D, Weinstock MA, Goodman C, et al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol. 2006;55:490–500.
    1. Berg M. Epidemiological studies of the influence of sunlight on the skin. Photodermatol. 1989;6:80–84.
    1. Bukvic Mokos Z, Kralj M, Basta-Juzbasic A, Lakos Jukic I. Seborrheic dermatitis: an update. Acta Dermatovenerol Croat. 2012;20:98–104.
    1. Misery L, Touboul S, Vincot C, Dutray S, Rolland-Jacob G, et al. Stress and seborrheic dermatitis. Ann Dermatol Venereol. 2007;134:833–837.
    1. Szepietowski JC, Reich A, Wesolowska-Szepietowska E, Baran E, National Quality of Life in Dermatology Group Quality of life in patients suffering from seborrheic dermatitis: influence of age, gender and education level. Mycoses. 2009;52:357–363.
    1. Peyri J, Lleonart M, Grupo español del Estudio SEBDERM Clinical and therapeutic profile and quality of life of patients with seborrheic dermatitis. Actas Dermosifiliogr. 2007;98:476–482.
    1. Mathes BM, Douglass MC. Seborrheic dermatitis in patients with acquired immunodeficiency syndrome. J Am Acad Dermatol. 1985;13:947–951.
    1. Osei-Sekyere B, Karstaedt AS. Immune reconstitution inflammatory syndrome involving the skin. Clin Exp Dermatol. 2010;35:477–481.
    1. Boehncke WH. Etiology and pathogenesis of psoriasis. Rheum Dis Clin North Am. 2015;41:665–675.
    1. Meadows-Oliver M. Tinea capitis: diagnostic criteria and treatment options. Pediatr Nurs. 2009;35:53–57.
    1. Tuzun Y, Wolf R, Kutlubay Z, Karakus O, Engin B. Rosacea and rhinophyma. Clin Dermatol. 2014;32:35–46.
    1. Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet. 2014;384:1878–1888.
    1. Valia RG. Etiopathogenesis of seborrheic dermatitis. Indian J Dermatol Venereol Leprol. 2006;72:253–255.
    1. Yamamoto T, Tsuboi R. Interleukin-2-induced seborrhoeic dermatitis-like eruption. J Eur Acad Dermatol Venereol. 2008;22:244–245.
    1. Reider N, Fritsch PO. Other eczematous eruptions. In: Bolognia JL, Jorizzo JL, Schaffer JV, editors. Dermatology. UK: Elsevier Health Sciences; 2012. pp. 219–221.
    1. Schwartz JR, Messenger AG, Tosti A, Todd G, Hordinsky M, et al. A comprehensive pathophysiology of dandruff and seborrheic dermatitis - towards a more precise definition of scalp health. Acta Derm Venereol. 2013;93:131–137.
    1. Pazyar N, Yaghoobi R, Bagherani N, Kazerouni A. A review of applications of tea tree oil in dermatology. Int J Dermatol. 2013;52:784–790.
    1. Satchell AC, Saurajen A, Bell C, Barnetson RS. Treatment of dandruff with 5% tea tree oil shampoo. J Am Acad Dermatol. 2002;47:852–855.
    1. Gaitanis G, Magiatis P, Hantschke M, Bassukas ID, Velegraki A. The Malassezia genus in skin and systemic diseases. Clin Microbiol Rev. 2012;25:106–141.
    1. Hay RJ. Malassezia dandruff and seborrhoeic dermatitis: an overview. Br J Dermatol. 2011;165(Suppl 2):2–8.
    1. Ro BI, Dawson TL. The role of sebaceous gland activity and scalp microfloral metabolism in the etiology of seborrheic dermatitis and dandruff. J Investig Dermatol Symp Proc. 2005;10:194–197.
    1. Rudramurthy SM, Honnavar P, Dogra S, Yegneswaran PP, Handa S, et al. Association of Malassezia species with dandruff. Indian J Med Res. 2014;139:431–437.
    1. Shuster S. The aetiology of dandruff and the mode of action of therapeutic agents. Br J Dermatol. 1984;111:235–242.
    1. Berk T, Scheinfeld N. Seborrheic dermatitis. P T. 2010;35:348–352.
    1. DeAngelis YM, Gemmer CM, Kaczvinsky JR, Kenneally DC, Schwartz JR, et al. Three etiologic facets of dandruff and seborrheic dermatitis: Malassezia fungi, sebaceous lipids, and individual sensitivity. J Investig Dermatol Symp Proc. 2005;10:295–297.
    1. Heng MC, Henderson CL, Barker DC, Haberfelde G. Correlation of Pityosporum ovale density with clinical severity of seborrheic dermatitis as assessed by a simplified technique. J Am Acad Dermatol. 1990;23:82–86.
    1. McGinley KJ, Leyden JJ, Marples RR, Kligman AM. Quantitative microbiology of the scalp in non-dandruff, dandruff, and seborrheic dermatitis. J Invest Dermatol. 1975;64:401–405.
    1. DeAngelis YM, Saunders CW, Johnstone KR, Reeder NL, Coleman CG, et al. Isolation and expression of a Malassezia globosa lipase gene, LIP1. J Invest Dermatol. 2007;127:2138–2146.
    1. Plotkin LI, Squiquera L, Mathov I, Galimberti R, Leoni J. Characterization of the lipase activity of Malassezia furfur. J Med Vet Mycol. 1996;34:43–48.
    1. Warner RR, Schwartz JR, Boissy Y, Dawson TL., Jr Dandruff has an altered stratum corneum ultrastructure that is improved with zinc pyrithione shampoo. J Am Acad Dermatol. 2001;45:897–903.
    1. Faergemann J, Bergbrant IM, Dohse M, Scott A, Westgate G. Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis: characterization of inflammatory cells and mediators in the skin by immunohistochemistry. Br J Dermatol. 2001;144:549–556.
    1. Breen PT. Canine seborrheic dermatitis. Vet Med Small Anim Clin. 1971;66:655–656.
    1. Eguchi-Coe Y, Valentine BA, Gorman E, Villarroel A. Putative Malassezia dermatitis in six goats. Vet Dermatol. 2011;22:497–501.
    1. Newcomer CE, Fox JG, Taylor RM, Smith DE. Seborrheic dermatitis in a rhesus monkey (Macaca mulatta) Lab Anim Sci. 1984;34:185–187.
    1. Pin D. Seborrhoeic dermatitis in a goat due to Malassezia pachydermatis. Vet Dermatol. 2004;15:53–56.
    1. Uzal FA, Paulson D, Eigenheer AL, Walker RL. Malassezia slooffiae-associated dermatitis in a goat. Vet Dermatol. 2007;18:348–352.
    1. Zouboulis CC, Akamatsu H, Stephanek K, Orfanos CE. Androgens affect the activity of human sebocytes in culture in a manner dependent on the localization of the sebaceous glands and their effect is antagonized by spironolactone. Skin Pharmacol. 1994;7:33–40.
    1. Niemann C, Horsley V. Development and homeostasis of the sebaceous gland. Semin Cell Dev Biol. 2012;23:928–936.
    1. Strauss JS, Downing DT, Ebling FJ. Sebaceous glands. In: Goldsmith LA, editor. Biochemistry and physiology of skin. New York: Oxford University Press; 1983. pp. 569–595.
    1. Burton JL, Pye RJ. Seborrhoea is not a feature of seborrhoeic dermatitis. Br Med J (Clin Res Ed) 1983;286:1169–1170.
    1. Ostlere LS, Taylor CR, Harris DW, Rustin MH, Wright S, et al. Skin surface lipids in HIV-positive patients with and without seborrheic dermatitis. Int J Dermatol. 1996;35:276–279.
    1. Harding CR. The stratum corneum: structure and function in health and disease. Dermatol Ther. 2004;17(Suppl 1):6–15.
    1. Turner GA, Hoptroff M, Harding CR. Stratum corneum dysfunction in dandruff. Int J Cosmet Sci. 2012;34:298–306.
    1. Sheu HM, Chao SC, Wong TW, Yu-Yun Lee J, Tsai JC. Human skin surface lipid film: an ultrastructural study and interaction with corneocytes and intercellular lipid lamellae of the stratum corneum. Br J Dermatol. 1999;140:385–391.
    1. Simon M, Tazi-Ahnini R, Jonca N, Caubet C, Cork MJ, et al. Alterations in the desquamation-related proteolytic cleavage of corneodesmosin and other corneodesmosomal proteins in psoriatic lesional epidermis. Br J Dermatol. 2008;159:77–85.
    1. Harding CR, Moore AE, Rogers JS, Meldrum H, Scott AE, et al. Dandruff: a condition characterized by decreased levels of intercellular lipids in scalp stratum corneum and impaired barrier function. Arch Dermatol Res. 2002;294:221–230.
    1. Rukwied R, Zeck S, Schmelz M, McGlone F. Sensitivity of human scalp skin to pruritic stimuli investigated by intradermal microdialysis in vivo. J Am Acad Dermatol. 2002;47:245–250.
    1. Birnbaum RY, Zvulunov A, Hallel-Halevy D, Cagnano E, Finer G, et al. Seborrhea-like dermatitis with psoriasiform elements caused by a mutation in ZNF750, encoding a putative C2H2 zinc finger protein. Nat Genet. 2006;38:749–751.
    1. Kerr K, Darcy T, Henry J, Mizoguchi H, Schwartz JR, et al. Epidermal changes associated with symptomatic resolution of dandruff: biomarkers of scalp health. Int J Dermatol. 2011;50:102–113.
    1. Sampaio AL, Nunes AP. School of Medicine. Rio de Janeiro, Brazil: Federal University of Rio de Janeiro; 2011. Study of frequency of human leukocyte antigen (HLA) in seborrheic dermatitis patients in a miscegenated population.
    1. Tsuji K, Nose Y, Ito M, Ozala A, Matsuo I. HLA antigens and susceptibility to psoriasis vulgaris in a non-Caucasian population. Tissue Antigens. 1976;8:29–33.
    1. Bergbrant IM, Johansson S, Robbins D, Scheynius A, Faergemann J, et al. An immunological study in patients with seborrhoeic dermatitis. Clin Exp Dermatol. 1991;16:331–338.
    1. Parry ME, Sharpe GR. Seborrhoeic dermatitis is not caused by an altered immune response to Malassezia yeast. Br J Dermatol. 1998;139:254–263.
    1. Ashbee HR, Ingham E, Holland KT, Cunliffe WJ. Cell-mediated immune responses to Malassezia furfur serovars A, B and C in patients with pityriasis versicolor, seborrheic dermatitis and controls. Exp Dermatol. 1994;3:106–112.
    1. Bergbrant IM, Andersson B, Faergemann J. Cell-mediated immunity to Malassezia furfur in patients with seborrhoeic dermatitis and pityriasis versicolor. Clin Exp Dermatol. 1999;24:402–406.
    1. Neuber K, Kroger S, Gruseck E, Abeck D, Ring J. Effects of Pityrosporum ovale on proliferation, immunoglobulin (IgA, G, M) synthesis and cytokine (IL-2, IL-10, IFN gamma) production of peripheral blood mononuclear cells from patients with seborrhoeic dermatitis. Arch Dermatol Res. 1996;288:532–536.
    1. Hoger H, Gialamas J, Adamiker D. Inherited seborrheic dermatitis--a new mutant in mice. Lab Anim. 1987;21:299–305.
    1. Hoger H, Gialamas J, Adamiker D. Reduced tumour incidence in mice with inherited seborrhoeic dermatitis. Lab Anim. 1994;28:340–346.
    1. Oble DA, Collett E, Hsieh M, Ambjorn M, Law J, et al. A novel T cell receptor transgenic animal model of seborrheic dermatitis-like skin disease. J Invest Dermatol. 2005;124:151–159.
    1. Hayashi K, Cao T, Passmore H, Jourdan-Le Saux C, Fogelgren B, et al. Progressive hair loss and myocardial degeneration in rough coat mice: reduced lysyl oxidase-like (LOXL) in the skin and heart. J Invest Dermatol. 2004;123:864–871.
    1. Cao T, Racz P, Szauter KM, Groma G, Nakamatsu GY, et al. Mutation in Mpzl3, a novel [corrected] gene encoding a predicted [corrected] adhesion protein, in the rough coat (rc) mice with severe skin and hair abnormalities. J Invest Dermatol. 2007;127:1375–1386.
    1. Leiva AG, Chen AL, Devarajan P, Chen Z, Damanpour S, et al. Loss of Mpzl3 function causes various skin abnormalities and greatly reduced adipose depots. J Invest Dermatol. 2014;134:1817–1827.
    1. Bhaduri A, Ungewickell A, Boxer LD, Lopez-Pajares V, Zarnegar BJ, et al. Network analysis identifies mitochondrial regulation of epidermal differentiation by MPZL3 and FDXR. Dev Cell. 2015;35:444–457.
    1. Burton JL, Cartlidge M, Cartlidge NE, Shuster S. Sebum excretion in parkinsonism. Br J Dermatol. 1973;88:263–266.
    1. Cowley NC, Farr PM, Shuster S. The permissive effect of sebum in seborrhoeic dermatitis: an explanation of the rash in neurological disorders. Br J Dermatol. 1990;122:71–76.
    1. Binder RL, Jonelis FJ. Seborrheic dermatitis in neuroleptic-induced parkinsonism. Arch Dermatol. 1983;119:473–475.
    1. Binder RL, Jonelis FJ. Seborrheic dermatitis: a newly reported side effect of neuroleptics. J Clin Psychiatry. 1984;45:125–126.
    1. Burton JL, Shuster S. Effect of L-dopa on seborrhoea of parkinsonism. Lancet. 1970;2:19–20.
    1. Burton JL, Cartlidge M, Shuster S. Effect of L-dopa on the seborrhoea of Parkinsonism. Br J Dermatol. 1973;88:475–479.
    1. Wilson CL, Walshe M. Incidence of seborrheic dermatitis in spinal injury patients. Br J Dermatol (suppl 33) 1988;119:48.
    1. Bettley FR, Marten RH. Unilateral seborrheic dermatitis following a nerve lesion. AMA Arch Derm. 1956;73:110–115.
    1. Ercis M, Balci S, Atakan N. Dermatological manifestations of 71 Down syndrome children admitted to a clinical genetics unit. Clin Genet. 1996;50:317–320.
    1. Rocha N, Velho G, Horta M, Martins A, Massa A. Cutaneous manifestations of familial amyloidotic polyneuropathy. J Eur Acad Dermatol Venereol. 2005;19:605–607.
    1. Hald M, Arendrup MC, Svejgaard EL, Lindskov R, Foged EK, et al. Evidence-based Danish guidelines for the treatment of Malassezia-related skin diseases. Acta Derm Venereol. 2015;95:12–19.
    1. Koc E, Arca E, Kose O, Akar A. An open, randomized, prospective, comparative study of topical pimecrolimus 1% cream and topical ketoconazole 2% cream in the treatment of seborrheic dermatitis. J Dermatolog Treat. 2009;20:4–9.
    1. Okokon EO, Verbeek JH, Ruotsalainen JH, Ojo OA, Bakhoya VN. Topical antifungals for seborrhoeic dermatitis. Cochrane Database Syst Rev. 2015;5:CD008138.
    1. Peter RU, Richarz-Barthauer U. Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebo-controlled trial. Br J Dermatol. 1995;132:441–445.
    1. Pierard-Franchimont C, Goffin V, Decroix J, Pierard GE. A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis. Skin Pharmacol Appl Skin Physiol. 2002;15:434–441.
    1. Segal R, David M, Ingber A, Lurie R, Sandbank M. Treatment with bifonazole shampoo for seborrhea and seborrheic dermatitis: a randomized, double-blind study. Acta Derm Venereol. 1992;72:454–455.
    1. Faergemann J. Seborrhoeic dermatitis and Pityrosporum orbiculare: treatment of seborrhoeic dermatitis of the scalp with miconazole-hydrocortisone (Daktacort), miconazole and hydrocortisone. Br J Dermatol. 1986;114:695–700.
    1. Dupuy P, Maurette C, Amoric JC, Chosidow O, Study Investigator Group Randomized, placebo-controlled, double-blind study on clinical efficacy of ciclopiroxolamine 1% cream in facial seborrhoeic dermatitis. Br J Dermatol. 2001;144:1033–1037.
    1. Ratnavel RC, Squire RA, Boorman GC. Clinical efficacies of shampoos containing ciclopirox olamine (1.5%) and ketoconazole (2.0%) in the treatment of seborrhoeic dermatitis. J Dermatolog Treat. 2007;18:88–96.
    1. Danby FW, Maddin WS, Margesson LJ, Rosenthal D. A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff. J Am Acad Dermatol. 1993;29:1008–1012.
    1. Gilbertson K, Jarrett R, Bayliss SJ, Berk DR. Scalp discoloration from selenium sulfide shampoo: a case series and review of the literature. Pediatr Dermatol. 2012;29:84–88.
    1. Reeder NL, Xu J, Youngquist RS, Schwartz JR, Rust RC, et al. The antifungal mechanism of action of zinc pyrithione. Br J Dermatol. 2011;165(Suppl 2):9–12.
    1. Shin H, Kwon OS, Won CH, Kim BJ, Lee YW, et al. Clinical efficacies of topical agents for the treatment of seborrheic dermatitis of the scalp: a comparative study. J Dermatol. 2009;36:131–137.
    1. Ortonne JP, Lacour JP, Vitetta A, Le Fichoux Y. Comparative study of ketoconazole 2% foaming gel and betamethasone dipropionate 0.05% lotion in the treatment of seborrhoeic dermatitis in adults. Dermatology. 1992;184:275–280.
    1. Elewski B. An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb Topical Cream) and desonide cream 0.05% in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face. Clin Dermatol. 2009;27(6 Suppl):S48–S53.
    1. Kircik LH. Treatment of scalp and facial seborrheic dermatitis with desonide hydrogel 0.05% J Clin Aesthet Dermatol. 2009;2:32–36.
    1. Pierard-Franchimont C, Pierard GE. A double-blind placebo-controlled study of ketoconazole + desonide gel combination in the treatment of facial seborrheic dermatitis. Dermatology. 2002;204:344–347.
    1. Kircik L. The evolving role of therapeutic shampoos for targeting symptoms of inflammatory scalp disorders. J Drugs Dermatol. 2010;9:41–48.
    1. Cook BA, Warshaw EM. Role of topical calcineurin inhibitors in the treatment of seborrheic dermatitis: a review of pathophysiology, safety, and efficacy. Am J Clin Dermatol. 2009;10:103–118.
    1. Kim BS, Kim SH, Kim MB, Oh CK, Jang HS, et al. Treatment of facial seborrheic dermatitis with pimecrolimus cream 1%: an open-label clinical study in Korean patients. J Korean Med Sci. 2007;22:868–872.
    1. Ozden MG, Tekin NS, Ilter N, Ankarali H. Topical pimecrolimus 1% cream for resistant seborrheic dermatitis of the face: an open-label study. Am J Clin Dermatol. 2010;11:51–54.
    1. Thaci D, Salgo R. Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies. Clin Dermatol. 2010;28:52–56.
    1. Kim HO, Yang YS, Ko HC, Kim GM, Cho SH, et al. Maintenance therapy of facial seborrheic dermatitis with 0.1% tacrolimus ointment. Ann Dermatol. 2015;27:523–530.
    1. Papp KA, Papp A, Dahmer B, Clark CS. Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults. J Am Acad Dermatol. 2012;67:e11–e15.
    1. Davies DB, Boorman GC, Shuttleworth D. Comparative efficacy of shampoos containing coal tar (4.0% w/w; Tarmed™), coal tar (4.0% w/w) plus ciclopirox olamine (1.0% w/w; Tarmed™ AF) and ketoconazole (2.0% w/w; Nizoral™) for the treatment of dandruff/seborrhoeic dermatitis. J Dermatolog Treat. 1999;10:177–183.
    1. Ballanger F, Tenaud I, Volteau C, Khammari A, Dreno B. Anti-inflammatory effects of lithium gluconate on keratinocytes: a possible explanation for efficiency in seborrhoeic dermatitis. Arch Dermatol Res. 2008;300:215–223.
    1. Dreno B, Moyse D. Lithium gluconate in the treatment of seborrhoeic dermatitis: a multicenter, randomised, double-blind study versus placebo. Eur J Dermatol. 2002;12:549–552.
    1. Stefanaki I, Katsambas A. Therapeutic update on seborrheic dermatitis. Skin Therapy Lett. 2010;15:1–4.
    1. Koca R, Altinyazar HC, Esturk E. Is topical metronidazole effective in seborrheic dermatitis? A double-blind study. Int J Dermatol. 2003;42:632–635.
    1. Seckin D, Gurbuz O, Akin O. Metronidazole 0.75% gel vs. ketoconazole 2% cream in the treatment of facial seborrheic dermatitis: a randomized, double-blind study. J Eur Acad Dermatol Venereol. 2007;21:345–350.
    1. Lee E, Koo J, Berger T. UVB phototherapy and skin cancer risk: a review of the literature. Int J Dermatol. 2005;44:355–360.
    1. Pirkhammer D, Seeber A, Honigsmann H, Tanew A. Narrow-band ultraviolet B (ATL-01) phototherapy is an effective and safe treatment option for patients with severe seborrhoeic dermatitis. Br J Dermatol. 2000;143:964–968.
    1. Reich A, Medrek K. Effects of narrow band UVB (311 nm) irradiation on epidermal cells. Int J Mol Sci. 2013;14:8456–8466.
    1. Das J, Majumdar M, Chakraborty U, Majumdar V, Mazumdar G, et al. Oral itraconazole for the treatment of severe seborrhoeic dermatitis. Indian J Dermatol. 2011;56:515–516.
    1. Kose O, Erbil H, Gur AR. Oral itraconazole for the treatment of seborrhoeic dermatitis: an open, noncomparative trial. J Eur Acad Dermatol Venereol. 2005;19:172–175.
    1. Gupta AK, Richardson M, Paquet M. Systematic review of oral treatments for seborrheic dermatitis. J Eur Acad Dermatol Venereol. 2014;28:16–26.
    1. Scaparro E, Quadri G, Virno G, Orifici C, Milani M. Evaluation of the efficacy and tolerability of oral terbinafine (Daskil) in patients with seborrhoeic dermatitis. A multicentre, randomized, investigator-blinded, placebo-controlled trial. Br J Dermatol. 2001;144:854–857.
    1. Vena GA, Micali G, Santoianni P, Cassano N, Peruzzi E. Oral terbinafine in the treatment of multi-site seborrhoic dermatitis: a multicenter, double-blind placebo-controlled study. Int J Immunopathol Pharmacol. 2005;18:745–753.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever